Abstract

BackgroundThe 2018 World Health Organization HIV guidelines were based on the results of a network meta-analysis (NMA) of published trials. This study employed individual patient-level data (IPD) and aggregate data (AgD) and meta-regression methods to assess the evidence supporting the WHO recommendations and whether they needed any refinements.MethodsAccess to IPD from three trials was granted through ClinicalStudyDataRequest.com (CSDR). Seven modelling approaches were applied and compared: 1) Unadjusted AgD network meta-analysis (NMA) – the original analysis; 2) AgD-NMA with meta-regression; 3) Two-stage IPD-AgD NMA; 4) Unadjusted one-stage IPD-AgD NMA; 5) One-stage IPD-AgD NMA with meta-regression (one-stage approach); 6) Two-stage IPD-AgD NMA with empirical-priors (empirical-priors approach); 7) Hierarchical meta-regression IPD-AgD NMA (HMR approach). The first two were the models used previously. Models were compared with respect to effect estimates, changes in the effect estimates, coefficient estimates, DIC and model fit, rankings and between-study heterogeneity.ResultsIPD were available for 2160 patients, representing 6.5% of the evidence base and 3 of 24 edges. The aspect of the model affected by the choice of modeling appeared to differ across outcomes. HMR consistently generated larger intervals, often with credible intervals (CrI) containing the null value. Discontinuations due to adverse events and viral suppression at 96 weeks were the only two outcomes for which the unadjusted AgD NMA would not be selected. For the first, the selected model shifted the principal comparison of interest from an odds ratio of 0.28 (95% CrI: 10.17, 0.44) to 0.37 (95% CrI: 0.23, 0.58). Throughout all outcomes, the regression estimates differed substantially between AgD and IPD methods, with the latter being more often larger in magnitude and statistically significant.ConclusionsOverall, the use of IPD often impacted the coefficient estimates, but not sufficiently as to necessitate altering the final recommendations of the 2018 WHO Guidelines. Future work should examine the features of a network where adjustments will have an impact, such as how much IPD is required in a given size of network.

Highlights

  • The 2018 World Health Organization HIV guidelines were based on the results of a network metaanalysis (NMA) of published trials

  • Overall, the use of individual patient-level data (IPD) often impacted the coefficient estimates, but not sufficiently as to necessitate altering the final recommendations of the 2018 World Health Organization (WHO) Guidelines

  • Future work should examine the features of a network where adjustments will have an impact, such as how much IPD is required in a given size of network

Read more

Summary

Introduction

The 2018 World Health Organization HIV guidelines were based on the results of a network metaanalysis (NMA) of published trials. This study employed individual patient-level data (IPD) and aggregate data (AgD) and meta-regression methods to assess the evidence supporting the WHO recommendations and whether they needed any refinements. Meta-analyses typically consist of combining aggregate data (AgD) results from publications. Two potential limitations to this form of meta-regression are: a limited number of data points to reliably estimate trends and risk of ecological fallacy (when trends at the trial-level do not match trends at the individual-level) [4]. A less common form of meta-regression involves using individual patient data (IPD), with or without AgD [5]. IPD metaanalysis can help overcome the two aforementioned limitations of AgD meta-regression [7]. Conducting meta-regression at patient-level values provide more data points, which lends itself better to simultaneously adjusting for multiple variables [8]

Objectives
Methods
Results
Conclusion
Full Text
Published version (Free)

Talk to us

Join us for a 30 min session where you can share your feedback and ask us any queries you have

Schedule a call